Vis enkel innførsel

dc.contributor.authorJensvoll, Hilde
dc.contributor.authorSeverinsen, Marianne T.
dc.contributor.authorHammerstrøm, Jens
dc.contributor.authorBrækkan, Sigrid Kufaas
dc.contributor.authorKristensen, Søren R.
dc.contributor.authorCannegieter, Suzanne C.
dc.contributor.authorBlix, Kristine
dc.contributor.authorTjønneland, Anne
dc.contributor.authorRosendaal, Frits Richard
dc.contributor.authorDziewiecka, Olga
dc.contributor.authorOvervad, Kim
dc.contributor.authorNæss, Inger Anne
dc.contributor.authorHansen, John-Bjarne
dc.date.accessioned2016-03-01T10:16:40Z
dc.date.accessioned2016-03-04T14:39:45Z
dc.date.available2016-03-01T10:16:40Z
dc.date.available2016-03-04T14:39:45Z
dc.date.issued2015
dc.identifier.citationClinical Epidemiology 2015, 7:401-410nb_NO
dc.identifier.issn1179-1349
dc.identifier.urihttp://hdl.handle.net/11250/2381511
dc.description.abstractBackground: Although venous thromboembolism (VTE) is a known common complication in cancer patients, there is limited knowledge on patient-related and cancer-specific risk factors in the general population. The Scandinavian Thrombosis and Cancer (STAC) Cohort was established by merging individual data from three large Scandinavian cohorts (The Tromsø Study, the second Nord-Trøndelag Health Study, and the Danish Diet, Cancer and Health Study). Here, we present the profile of the STAC cohort and provide age-specific incidence rates of VTE and cancer Methods: The STAC cohort includes 144,952 subjects aged 19–101 years without previous VTE or cancer. Baseline information collected in 1993–1997 included physical examination, self-administered questionnaires, and blood samples. Validated VTE events and cancer diagnoses were registered up to 2007–2012. Results: There were 2,444 VTE events (1.4 per 1,000 person-years [PY]) during follow-up, and the incidence increased exponentially from 0.3 per 1,000 PY in subjects aged 20–29 years to 6.4 per 1,000 PY in subjects aged 80+. Overall, 51% of the VTE events were provoked, and cancer was the most common provoking factor (19%), followed by immobilization and surgery (both 15%). In total, 19,757 subjects developed cancer during follow-up (9.8 per 1,000 PY), and the 5-year age-specific incidence rates of cancer were coherent with corresponding rates from the Norwegian Cancer Registry. Conclusion: The STAC cohort will provide a unique opportunity to explore the epidemiology and impact of genetic and environmental patient-related and cancer-specific risk factors for VTE in the general population. Keywords: venous thromboembolism, incidence rates, person-years, pulmonary embolism, population-based cohort, prospective, cancernb_NO
dc.language.isoengnb_NO
dc.publisherDove Medical Pressnb_NO
dc.titleExisting data sources in clinical epidemiology: The Scandinavian Thrombosis and Cancer Cohortnb_NO
dc.typePeer reviewednb_NO
dc.typeJournal articleen_GB
dc.date.updated2016-03-01T10:16:40Z
dc.source.volume7nb_NO
dc.source.journalClinical Epidemiologynb_NO
dc.identifier.doi10.2147/CLEP.S84279
dc.identifier.cristin1285529
dc.description.localcodeThis work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.nb_NO


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel